EIM
NMTC icon

Essex Investment Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Essex Investment Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$203K Buy
43,659
+12,254
+39% +$58.9K 0.03% 200
2025
Q4 		$143K Buy
+31,405
New +$143K 0.02% 221

Other funds holding NMTC

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Essex Investment Management's NMTC Position: Q1 2026 in Review

Essex Investment Management increased its NeuroOne Medical Technologies (NMTC) stake by 39% in Q1 2026, buying an estimated $58.9K and bringing the position to 43,659 shares worth $203K. The position accounts for 0.03% of the portfolio, ranked #200.

Essex Investment Management first reported a position in NMTC in Q4 2025 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold NMTC as of Q1 2026.

  • Essex Investment Management held 43,659 shares of NeuroOne Medical Technologies worth $203K as of Q1 2026.
  • Essex Investment Management bought 12,254 NeuroOne Medical Technologies shares in Q1 2026, an estimated $58.9K.
  • NeuroOne Medical Technologies made up 0.03% of Essex Investment Management's portfolio in Q1 2026, its #200 holding.
  • Essex Investment Management first reported a position in NeuroOne Medical Technologies in Q4 2025 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q1 2026.

Based on Essex Investment Management's 13F filing for Q1 2026, filed 11 May 2026.